HSBC assigns a ‘Buy’ to JSW Steel, Jindal Stainless

HSBC has initiated coverage on JSW Steel and Jindal Stainless with Buy ratings, anticipating a multi-year demand upcycle fueled by infrastructure and urbanization. The bank also reiterated a Buy on Tata Steel, highlighting strong balance sheets and margin expansion as key sector tailwinds, with price targets implying significant upside.

Rupee under pressure from oil, dollar demand

The Indian rupee weakened significantly on Tuesday, closing at 94.54 against the US dollar. Rising oil prices and strong dollar demand from importers pressured the currency. Traders noted the Reserve Bank of India likely intervened to curb further losses. Elevated oil prices and global trade uncertainties are creating a negative sentiment for the rupee.

New launches, capacity hike to lift Maruti Suzuki facing a war squeeze

Maruti Suzuki’s March quarter net profit declined due to mark-to-market losses, input costs, and production constraints. The company is expanding capacity and expects margin improvement by FY30, driven by SUV launches and EV growth. Despite short-term pressures, FY26 saw record volumes and sales.

Peak XV exits One MobiKwik Systems in Rs 130 crore block deal: Report

Venture capital firm Peak XV Partners has exited Indian fintech One MobiKwik Systems. The firm sold its stake for over Rs 130 crore. This exit follows One MobiKwik’s significant milestone. The Reserve Bank of India approved its application for a Non-Banking Financial Company license. This approval allows the company to launch a new lending arm.

Broader markets rally! These 10 smallcap stocks jumped up to 57% in April so far

Indian stock markets have made a partial recovery in April so far, following the incessant March selloff triggered by the onset of the Iran-US war. Interestingly, broader markets have outperformed benchmarks during this period, with Nifty Smallcap 250 index rallying around 17% so far this month, eclipsing Nifty’s 8% surge in the same period. Here […]

Sun Pharma-Organon deal: How a $12-billion merger will reshape India’s pharma landscape

Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The deal leverages Organon’s strengths in women’s health, biosimilars, and established brands, aiming for significant growth despite geopolitical concerns. Integration plans and manageable debt are key to the strategic move.